Decera Clinical Education Infectious Disease Podcast

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV.

Topics include:

Considerations for CMV management in HCT recipients

New definitions of refractory and resistant CMV 

Risk factors for refractory and resistant CMV infections

Identifying drug-resistant CMV 

Treatment options for refractory/resistant CMV

To view the full educational program and download the accompanying slides, visit our website:
https://bit.ly/4lfrDTT

Presenters:

Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID

Professor and Chair

G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases

President, The International Immunocompromised Host Society (ICHS)

Director, Clinical Virology Research

Department of ID/IC/EH

UT MD Anderson Cancer Center

Houston, Texas

Marcus Pereira, MD, MPH, FAST

Associate Professor of Medicine

Director of Clinical Services, Division of Infectious Diseases

Medical Director, Transplant Infectious Disease Program

Columbia University Irving Medical Center

New York, New York

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID and Marcus Pereira, MD, MPH, FAST, discuss the burden of CMV in HCT recipients and explore strategies effectively identify and monitor high-risk patients. Topics include:

Epidemiology of CMV among HCT recipients

Direct and indirect effects of CMV after HCT

Dynamics of risk factors for CMV infection 

Strategies for prevention of CMV infection

To view the full educational program and download the accompanying slides, visit our website:
https://bit.ly/4lfrDTT

Presenters:

Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID

Professor and Chair

G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases

President, The International Immunocompromised Host Society (ICHS)

Director, Clinical Virology Research

Department of ID/IC/EH

UT MD Anderson Cancer Center

Houston, Texas

Marcus Pereira, MD, MPH, FAST

Associate Professor of Medicine

Director of Clinical Services, Division of Infectious Diseases

Medical Director, Transplant Infectious Disease Program

Columbia University Irving Medical Center

New York, New York

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, experts Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH; Ruth Carrico, PhD, DNP, FNP-C, FAAN; and Dalilah Restrepo, MD, discuss improving shingles vaccine uptake. Topics covered include: 
The Burden of Shingles
Care Coordination Between Primary and Specialty Care
Promoting Shingles Vaccine Series Completion
Addressing Disparities in Shingles Vaccine Access and Uptake
 
Presenters:
Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH
Associate Professor of Clinical Pharmacy
University of California, San Diego
Department of Pharmacy Practice and Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences
Division of the Black Diaspora and African American Studies
La Jolla, California
Ruth Carrico, PhD, DNP, FNP-C, FAAN
Senior Partner
Carrico & Ramirez PLLC
Professor, Adjunct
Division of Infectious Diseases
University of Louisville School of Medicine
Louisville, Kentucky
Dalilah Restrepo, MD
Infectious Diseases Specialist
University of California, Irvine
Los Alamitos Hospital
Orange County, California

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.
Topics covered include:
Mechanisms of pruritus and fatigue in PBC
Nonpharmacologic treatment options
An overview of clinical trial data supporting second-line agents for symptom management:
Bezafibrate
Elafibranor
Seladelpar
Investigational agents:
Volixibat
Linerixibat
Setanaxib
This episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:
https://bit.ly/44ZJ5os
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD, 
MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.
Topics covered include:
Available agents for second-line treatment of PBC
An overview of clinical trial data supporting second-line agents:
Obeticholic acid (OCA)
Bezafibrate
Elafibranor
Seladelpar
This episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3r
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD, MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.